Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;3(5):529-39.
doi: 10.1039/c0ib00142b. Epub 2011 Mar 8.

Bioengineering approaches to study multidrug resistance in tumor cells

Affiliations
Review

Bioengineering approaches to study multidrug resistance in tumor cells

Brian Fallica et al. Integr Biol (Camb). 2011 May.

Abstract

The ability of cancer cells to become resistant to chemotherapeutic agents is a major challenge for the treatment of malignant tumors. Several strategies have emerged to attempt to inhibit chemoresistance, but the fact remains that resistance is a problem for every effective anticancer drug. The first part of this review will focus on the mechanisms of chemoresistance. It is important to understand the environmental cues, transport limitations and the cellular signaling pathways associated with chemoresistance before we can hope to effectively combat it. The second part of this review focuses on the work that needs to be done moving forward. Specifically, this section focuses on the necessity of translational research and interdisciplinary directives. It is critical that the expertise of oncologists, biologists, and engineers be brought together to attempt to tackle the problem. This discussion is from an engineering perspective, as the dialogue between engineers and other cancer researchers is the most challenging due to non-overlapping background knowledge. Chemoresistance is a complex and devastating process, meaning that we urgently need sophisticated methods to study the process of how cells become resistant.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Multiple mechanisms (in red), under the control of multiple extracellular conditions, are responsible for the development of the resistant phenotype.
Fig. 2
Fig. 2
The expertise from oncologists and tissue engineers will need to be merged in order to create a successful in vitro cancer model that can recreate complex tumor processes such as chemoresistance.

References

    1. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57:1–134. - PubMed
    1. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–458. - PubMed
    1. Frei E, Freireich EJ, Gehan E, et al. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood. 1961;18:431–454.
    1. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med. 2006;145:702–703. - PubMed
    1. Denis GV. Imatinib mesylate (Gleevec®) and the emergence of chemotherapeuticss drug-resistant mutations. Mol Target Oncol. 2008:545–558.

Publication types

Substances